PER Podcast Sessions

PER Podcast Sessions

Download on the App Store

PER Podcast Sessions episodes

  • S2 Ep36: Medical Crossfire: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
    Thanks for your interest in this podcast. Please read this important program information before listening. 


    Episode Description

    In this podcast, experts Mohamad Mohty, MD, PhD and Surbhi Sidana, MD discuss recent advances in treating and managing newly diagnosed multiple myeloma (NDMM).


    Learning Objectives 

    Upon successful completion of this activity, you should be better prepared to:

    • Analyze efficacy and safety data from recent clinical trials evaluating quadruplet therapy in patients with newly diagnosed multiple myeloma (NDMM)

    Acknowledgment of Educational Grant Support

    This activity is supported by an educational grant from Sanofi.


    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Instructions on How to Receive Credit

    1.      Listen to this podcast in its entirety. 
    2.      Go to gotoper.com/credit and enter code: 8342
    3.      Answer the evaluation questions.
    4.      Request credit using the drop-down menu.
    You may immediately download your certificate.


    Faculty:

    Mohamad Mohty, MD, PhD
    Professor of Hematology
    Head of the Hematology and Cellular Therapy Department, Saint-Antoine
    Hospital
    Sorbonne University
    Paris, France

    Disclosures: Consulting Fees: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Novartis, Pfizer, Sanofi, Stemline, Takeda; Grants and contracts from an entity: Janssen, Novartis, Sanofi; Manuscript writing or educational events: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Payment or honoraria for lectures: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Presentations: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Speakers’ Bureau: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda.


    Surbhi Sidana, MD
    Associate Professor of Medicine
    Director, Myeloma Disease Focused Group
    Division of BMT & Cell Therapy
    Stanford University
    Stanford, CA

    Disclosures: Consulting or Advisory role: AbbVie, Arcellx, Bioline, Bristol Myers Squibb, Genentech, Janssen, Kite, Legend, Pfizer, Regeneron, Roche, Sanofi, Takeda; Research funding: Allogene Therapeutics, Bristol Myers Squibb, Janssen, Magenta Therapeutics, Novartis.


    Faculty, Staff, and Planners’ Disclosures
    In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

    The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 


    This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an artificial intelligence tool.


    To learn more about this topic—including information on using minimal residual disease assessment to guide the choice and duration of maintenance therapy, balancing disease- and patient-specific factors to formulate individualized treatment plans, and implementing proactive measures to mitigate treatment-related adverse events in patients with NDMM—go to https://www.gotoper.com/aom-25-ndmm-full-archive-activity 
    Release Date

    July 30, 2025

    Expiration Date

    July 30, 2026


    Off-Label Disclosure and Disclaimer

    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
    36 min
  • S2 Ep35: Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
    Thanks for your interest in this podcast. Please read this important program information before listening. 


    Episode Description 

    In this podcast, experts Mohamad Mohty, MD, PhD and Surbhi Sidana, MD discuss recent advances in treatment options for relapsed/refractory multiple myeloma (R/R MM).

    Learning Objectives 

    Upon successful completion of this activity, you should be better prepared to:

    • Analyze efficacy and safety data from pivotal trials evaluating new and emerging therapies for relapsed/refractory multiple myeloma (R/R MM)

    Acknowledgment of Educational Grant Support

    This activity is supported by an educational grant from AbbVie, Inc.


    Faculty:

    Mohamad Mohty, MD, PhD
    Professor of Hematology
    Head of the Hematology and Cellular Therapy Department, Saint-Antoine
    Hospital
    Sorbonne University
    Paris, France

    Disclosures: Consulting Fees: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Novartis, Pfizer, Sanofi, Stemline, Takeda; Grants and contracts from an entity: Janssen, Novartis, Sanofi; Manuscript writing or educational events: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Payment or honoraria for lectures: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Presentations: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Speakers’ Bureau: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda.


    Surbhi Sidana, MD
    Associate Professor of Medicine
    Director, Myeloma Disease Focused Group
    Division of BMT & Cell Therapy
    Stanford University
    Stanford, CA

    Disclosures: Consulting or Advisory role: AbbVie, Arcellx, Bioline, Bristol Myers Squibb, Genentech, Janssen, Kite, Legend, Pfizer, Regeneron, Roche, Sanofi, Takeda; Research funding: Allogene Therapeutics, Bristol Myers Squibb, Janssen, Magenta Therapeutics, Novartis.


    Faculty, Staff, and Planners’ Disclosures
    In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

    The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

    This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an artificial intelligence tool.


    To learn more about this topic, including information on strategies for balancing disease- and patient-specific factors in early relapsed multiple myeloma (MM) treatment plans, evidence-based strategies to select and sequence T-cell therapies for heavily pretreated patients with relapsed/refractory (R/R) MM, and proactive measures to mitigate treatment-related toxicities in patients with R/R MM, go to https://www.gotoper.com/aom-25-rrmm-full-archive-activity

    Release Date

    July 30, 2025

    Expiration Date

    July 30, 2026 


    Off-Label Disclosure and Disclaimer

    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

    29 min
  • S2 Ep44: PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC – Expert Perspectives on New Approvals and Emerging Strategies
    Thanks for your interest in this podcast. Please read this important program information before listening. 

    Episode Description
    In this podcast, experts Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; and Misty D. Shields, MD, PhD; discuss recent advances and emerging approaches—including immunotherapy, DLL3-targeted agents, and antibody-drug conjugates—for patients with small cell lung cancer (SCLC). 

    Learning Objectives 
    Upon successful completion of this activity, you should be better prepared to:
    • Discuss current trial data describing novel strategies for the management of limited- and extensive-stage SCLC
    • Apply clinical trial evidence supporting the efficacy and safety of SCLC treatment across lines of care in real-world case-based scenarios
    • Acknowledgment of Educational Grant Support
      This activity is supported by educational grants from Amgen, Inc; AstraZeneca; and Boehringer Ingelheim, Inc.

      Accreditation/Credit Designation
      Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      Instructions on How to Receive Credit
      1.       Listen to this podcast in its entirety. 
      2.       Go to gotoper.com/credit and enter code: 5789
      3.       Answer the evaluation questions.
      4.       Request credit using the drop-down menu.
      You may immediately download your certificate.

      Chair:
      Jonathan W. Goldman, MD
      Professor of Medicine, Division of Hematology & Oncology
      Director of Clinical Trials in Thoracic Oncology
      Associate Director of Drug Development
      University of California, Los Angeles
      Santa Monica, CA 

      Disclosures (Dr Goldman): Consultant: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, Janssen, Pfizer, Summit; Grant/Research Support: AbbVie, Agenus, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, GSK, Janssen, Merck, Pfizer, Puma, RayzeBio, Summit, Tango

      Faculty:
      Percy Lee, MD, FASTRO
      Medical Director, Orange County and Coastal Regions
      Department of Radiation Oncology
      City of Hope National Medical Center
      Irvine, CA

      Disclosures: Advisory Board: AstraZeneca, Johnson & Johnson; Consultant: AstraZeneca, Genentech, Johnson & Johnson, Roche; Grant/Research Support: AstraZeneca; Honoraria Recipient: AstraZeneca, Genentech, Johnson & Johnson, Roche

      Erminia Massarelli, MD, PhD, MS
      Division Chief of Hematology/Oncology
      Professor of Medicine
      University of Texas Tyler School of Medicine
      Tyler, TX

      Disclosures (Dr Massarelli): Adviser: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Johnson & Johnson/Janssen, Sanofi; Consultant: AbbVie

      Misty D. Shields, MD, PhD
      Assistant Professor of Clinical Medicine
      Adjunct Assistant Professor of Medical and Molecular Genetics
      Associate Member, Experimental and Developmental Therapeutics
      Department of Medicine, Division of Hematology/Oncology, Thoracic Oncology
      Melvin & Bren Simon Comprehensive Cancer Center
      Indiana University School of Medicine
      Indianapolis, IN

      Disclosures (Dr Shields): Advisory Board: AstraZeneca; Speakers’ Bureau: Jazz Pharmaceuticals; Steering Committee: AstraZeneca

      Faculty, Staff, and Planners’ Disclosures
      In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

      The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

      This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

      To learn more about this topic, including information on new agents and approaches in small cell lung cancer, go to https://www.gotoper.com/annual-oncology-meeting-25-sclc-activity.
      Release Date
      July 30, 2025

      Expiration Date
      July 30, 2026

      Off-Label Disclosure and Disclaimer
      This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

      22 min
    • S2 Ep40: Tumor Board: Expert Insights on Managing Classical EGFR Mutations, EGFR Exon 20 Insertions, and Atypical EGFR Mutations in Metastatic NSCLC
      Thanks for your interest in this podcast. Please read this important program information before listening. 

      Episode Description
      In this podcast, experts Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; and Julia Rotow, MD; discuss the latest evidence in managing EGFR-mutated non–small cell lung cancer (NSCLC), with a focus on personalized treatment strategies based on factors such as molecular profile, disease burden, and patient fitness. 

      Learning Objectives 
      Upon successful completion of this activity, you should be better prepared to:
      ·  Outline current and emerging treatment strategies for EGFR-mutated metastatic NSCLC

      ·  Integrate recent data and guideline-based recommendations when developing personalized care plans for patients with EGFR-mutated metastatic NSCLC

      ·  Identify appropriate strategies for the prevention and management of toxicities associated with EGFR-targeting therapies for metastatic NSCLC

      Acknowledgment of Educational Grant Support
      This activity is supported by an educational grant from Black Diamond Therapeutics.

      Accreditation/Credit Designation
      Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

      Instructions on How to Receive Credit
      1.       Listen to this podcast in its entirety. 
      2.       Go to gotoper.com/credit and enter code: 7235
      3.       Answer the evaluation questions.
      4.       Request credit using the drop-down menu.
      You may immediately download your certificate.

      Chair:
      Balazs Halmos, MD, MS 
      Professor of Clinical Medicine 
      Director, Thoracic/Head and Neck Oncology
      Director, Clinical Cancer Genomics 
      Albert Einstein College of Medicine/Montefiore Medical Center 
      Bronx, NY

      Disclosures: Consultant: Apollomics, AstraZeneca, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Genentech, GSK, Johnson & Johnson, Merck, Pfizer, Takeda; DSMC: Apollomics, BMS, City of Hope, eFFECTOR, Nuvalent, TPT; Research grant (paid to institution): AbbVie, Advaxis, Amgen, ArriVent, AstraZeneca, BeiGene, Black Diamond Therapeutics, BMS, Boehringer Ingelheim, Daiichi Sankyo, Forward Pharma, GSK, Janssen, Merck, Numab, Pfizer.

      Faculty
      Enriqueta Felip, MD, PhD

      Professor of Medicine, Universitat Autònoma de Barcelona (UAB)
      Section in Chief, Medical Oncology Department 
      Director, Thoracic Oncology Unit 
      Vall d’Hebron University Hospital 
      Vall d’Hebron Institute of Oncology (VHIO) 
      Barcelona, Spain

      Disclosures: Consulting Fee: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daichii Sankyo, F. Hoffmann-La Roche, Gilead, Glaxo Smith Kline, Janssen, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi, Turning Point; Independent Member of the Board: Grifols; Speaker’ Bureau: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Gilead, Janssen, Johnson & Johnson, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, Novartis, PeerVoice, Pfizer, Regeneron, Takeda; Support for Attending Meetings/Travel: AstraZeneca, Johnson & Johnson, Roche.

      Julia Rotow, MD
      Assistant Professor
      Harvard Medical School
      Clinical Director, Lowe Center for Thoracic Oncology
      Dana-Farber Cancer Institute
      Boston, MA

      Disclosures: Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squib, Daiichi Sankyo, Genentech, Gilead, Jazz, Johnson & Johnson, Merus, Novocure, Pfizer; Contracted for Research (to institution): AbbVie, Altor Bioscience, AstraZeneca, Bicycle Therapeutics, BioAtla, Black Diamond Therapeutics, Blueprint Medicines, Duality, Enliven Therapeutics, EpimAb, Immunity Bio, LOXO Oncology, ORIC Pharmaceuticals, RedCloud Bio, Regeneron, Summit, Synthekine; Honoraria: AstraZeneca, Daiichi Sankyo, Pfizer.

      Faculty, Staff, and Planners’ Disclosures
      In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

      The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

      This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
      To learn more about this topic, including information on biomarker testing and managing patients with atypical EGFR mutations, go to https://www.gotoper.com/annual-oncology-meeting-25-egfrnsclc-activity

      Release Date
      July 30, 2025

      Expiration Date
      July 30, 2026

      30 min
    • S2 Ep39: Medical Crossfire: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches
      Thanks for your interest in this podcast. Please read this important program information before listening. 

      Episode Description
      In this podcast, experts Gabriela Hobbs, MD; John O. Mascarenhas, MD; and Naveen Pemmaraju, MD; discuss recent advances in therapies for myelofibrosis (MF), polycythemia vera (PV), and essential thrombocytopenia (ET).

      Learning Objectives 
      Upon successful completion of this activity, you should be better prepared to:
      ·  Analyze the latest data on current and emerging therapies for MF, PV, and ET
      ·  Create an evidence-based treatment plan for a patient with MF, PV, or ET that balances patient-, disease-, and treatment-related considerations

      Acknowledgment of Educational Grant Support
      This activity is supported by educational grants from Geron, Incyte Corporation, and PharmaEssentia.
      Accreditation/Credit Designation
      Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      Instructions on How to Receive Credit
      1.  Listen to this podcast in its entirety. 
      2. Go to gotoper.com/credit and enter code: 5231
      3.  Answer the evaluation questions.
      4.  Request credit using the drop-down menu.

      You may immediately download your certificate. 

      Faculty:
      Gabriela Hobbs, MD
      Assistant Professor
      Harvard Medical School
      Clinical Director, Leukemia Service
      Massachusetts General Hospital
      Cambridge, MA
      Disclosures: Advisor: Bristol Myers Squibb, GSK, Incyte, Novartis, Pfizer, Sobi; Consultant: Cogent, Merck, PharmaEssentia; Grant/Research Support: Incyte.

      John Mascarenhas, MD
      Professor of Medicine
      Icahn School of Medicine at Mount Sinai
      Director, Center of Excellence in Blood Cancers and Myeloid Disorders
      Director, Adult Leukemia Program Leader, Myeloproliferative Disorders Clinical Research Program
      Tisch Cancer Institute, Division of Hematology/Oncology
      New York, NY
      Disclosures: Consultant: AbbVie, AJAX, Bristol Myers Squibb, CTI/SOBI, Disc, Galecto, Geron, GSK, Incyte, Kartos, Karyopharm, Keros, Merck, Novartis, Pfizer, PharmaEssentia, Roche, Sumitomo; Grant/Research Support: AbbVie, AJAX, Bristol Myers Squibb, CTI/SOBI, Geron, Incyte, Kartos, Karyopharm, Novartis, PharmaEssentia.

      Naveen Pemmaraju, MD
      Professor, Department of Leukemia
      Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
      Executive Director, MDACC Cancer Network for Cancer Medicine
      The University of Texas MD Anderson Cancer Center
      Houston, TX
      Disclosures: Advisory Board: AbbVie, Bristol Myers Squibb Consulting, CTI BioPharma, GSK Consulting, Immunogen, Incyte, Johnson & Johnson, Karyopharm, Menarini-Stemline Group, MorphoSys, Pacylex, Protagonist; Board of Directors/Management: Dan's House of Hope; Consultant: AbbVie, Bristol Myers Squibb Consulting, CTI BioPharma, GSK Consulting, Immunogen, Incyte, Johnson & Johnson, Karyopharm, Menarini-Stemline Group, MorphoSys, Pacylex, Protagonist; Grant/Research Support: Sager Strong Foundation, United States Department of Defense (DOD); Speakers’ Bureau: AbbVie, Bristol Myers Squibb Consulting, CTI BioPharma, GSK Consulting, Immunogen, Incyte, Johnson & Johnson, Karyopharm, Menarini-Stemline Group, MorphoSys, Pacylex, Protagonist.

      Faculty, Staff, and Planners’ Disclosures
      In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

      The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. 

      This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

      To learn more about this topic, including information on applying best practices for identifying and managing treatment-related adverse events and strategies for implementing supportive care approaches to address symptom burden, go to https://www.gotoper.com/annual-oncology-meeting-25-mfpv-activity
       
      Release Date
      July 30, 2025

      Expiration Date
      July 30, 2026

      Off-Label Disclosure and Disclaimer
      This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

      22 min
    • S2 Ep38: Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer
      Thank you for your interest in this podcast. Please read this important program information before listening. 

      Episode Description
      In this podcast, experts Rachel N. Grisham, MD; Oladapo O. Yeku, MD, PhD, FACP; and Ramez N. Eskander, MD, explore new frontiers in the treatment of ovarian cancer, including advances in biomarker-driven decision-making, maintenance strategies, and emerging targeted therapies. The discussion covers the evolving role of PARP inhibitors, the impact of HRD and BRCA testing, and the integration of antibody-drug conjugates into treatment plans for patients with recurrent disease.

      Learning Objectives 
      Upon successful completion of this activity, you should be better prepared to:
      1.  Assess the role of molecular and biomarker testing—including BRCA, HRD, and FRα—in guiding personalized treatment decisions and optimizing maintenance strategies in ovarian cancer.
      2.  Incorporate recent clinical trial data on PARP inhibitors, antibody-drug conjugates, and novel combinations to inform the sequencing and integration of emerging therapies into clinical practice.

      Acknowledgment of Educational Grant Support
      This activity is supported by educational grants from AbbVie, Inc; and Corcept Therapeutics Incorporated. 

      Accreditation/Credit Designation
      Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      Instructions on How to Receive Credit
      1.  Listen to this podcast in its entirety. 
      2.  Go to gotoper.com/credit and enter code: 6325
      3.  Answer the evaluation questions.
      4.  Request credit using the drop-down menu.
      You may immediately download your certificate.

      Chair
      Rachel N. Grisham, MD

      Associate Attending Physician
      Division of Solid Tumor Oncology
      Section Head, Ovarian Cancer
      Director, Gynecologic Medical Oncology, MSK Westchester
      Memorial Sloan Kettering Cancer Center
      New York, NY
      Disclosures: Consulting/Advisory Board: AstraZeneca, Corcept, Genmab, GOG Foundation, GSK, Incyclix, Incyte, SpringWorks, Verastem. 

      Faculty
      Ramez N. Eskander, MD
      Professor of Gynecologic Oncology
      Medical Director, Clinical Trials Office
      Fellowship Program Director
      UC San Diego Moores Cancer Center
      La Jolla, CA
      Disclosures: Advisory Board:AbbVie, AstraZeneca, Daiichi Sankyo, Eisai, GSK, MSD, Myriad, Nuvectis, Pfizer, PMV Pharma, Regeneron; Honoraria: MSD.

      Oladapo Yeku, MD, PhD, FACP
      Assistant Professor
      Harvard Medical School
      Director of Translational Research, Gynecologic Oncology Program
      Massachusetts General Hospital
      Boston, MA
      Disclosures: Advisory Board Member: HC Bioscience; Contracted Research: Ascendis Pharma, BioNTech, Immunocore Limited, Merck Sharp & Dohme, ProfoundBio 

      Faculty, Staff, and Planners’ Disclosures
      In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

      The staff of Physicians’ Education Resource®, LLC, has no relevant financial relationships with ineligible companies.  

      This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

      To learn more about this topic, including information of the live presentation program Show Me the Data New Frontiers in the Treatment of Ovarian Cancer program held on Saturday, May 31, 2025, in Chicago, Illinois, go to https://www.gotoper.com/annual-oncology-meeting-25-ovarian-activity

      Release Date
      July 30, 2025

      Expiration Date
      July 30, 2026

      Off-Label Disclosure and Disclaimer
      This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

      33 min
    • S2 Ep34: PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)
      Episode Description

      In this podcast, ALS expert Terry Heiman-Patterson, MD, discusses best practices for ALS diagnosis and use of targeted therapy.

      Learning Objectives 

      Upon successful completion of this activity, you should be better prepared to:

      • Apply recommended diagnostic criteria and strategies to make an early, accurate diagnosis of ALS
      • Discuss the mechanisms of action, efficacy, and safety of approved and emerging treatments for patients with ALS

      • Acknowledgment of Educational Grant Support

        This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America.

        Accreditation/Credit Designation

        Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

        Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

        Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hours.

        Instructions on How to Receive Credit

        1. Listen to this podcast in its entirety. 
        2. Go to gotoper.com/credit and enter code: 6322
        3. Answer the evaluation questions.
        4. Request credit using the drop-down menu.
        5. You may immediately download your certificate.
          Chair:

          Terry Heiman-Patterson, MD

          Professor, Neurology, Lewis Katz School of Medicine at Temple University
          Director, Temple MDA/ALS Center of Hope
          Philadelphia, PA

          Faculty, Staff, and Planners’ Disclosures

          In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

          The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

          This podcast was developed by PER® editorial staff based on an online activity developed with these faculty.

          Release Date

          June 30, 2025
          Expiration Date

          Jun 30, 2026

          Off-Label Disclosure and Disclaimer

          This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
          27 min
        6. S2 Ep33: PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)
          Episode Description

          In this podcast, ALS expert clinician-researcher Richard Bedlack MD, PhD, discusses targeted therapy for ALS and the role of individualized, multidisciplinary care to optimize patient outcomes.

          Learning Objectives 

          Upon successful completion of this activity, you should be better prepared to:

          • Discuss the mechanisms of action, efficacy, and safety of approved and emerging treatments for patients with ALS
          • Develop individualized, multidisciplinary ALS management plans in collaboration with the patient and caregiver
          • Acknowledgment of Educational Grant Support

            This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America.

            Accreditation/Credit Designation

            Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

            Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

            Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hours.

            Instructions on How to Receive Credit

            1. Listen to this podcast in its entirety. 
            2. Go to gotoper.com/credit and enter code: 3543
            3. Answer the evaluation questions.
            4. Request credit using the drop-down menu.

            5. You may immediately download your certificate.

              Chair:

              Richard Bedlack, MD, PhD

              Stewart, Hughes, and Wendt Distinguished Professor
              Director of ALS Program
              Duke University Department of Neurology
              Durham, NC

              Disclosures: Consultant: AB Science, Advarra, ALS Association, Amylyx, Biogen Idec, Capvision, CareSpace Health, ClearView, Compassionate Care ALS, Eikonoklastes, Guidepoint Global, Health Advances, Health Care Strategy Partners, Ionis Pharmaceuticals, Kaplan, KeyQuest, Med-IQ, NeuroSense, Novartis, Prime Education, PTC Therapeutics, Roon; Research Support: Healey Center, MediciNova; Advisory Board: GenieUs; Other: Biogen, Ionis, NeuroSense, PTC.
              Faculty, Staff, and Planners’ Disclosures
              In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

              The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

              This podcast was developed by PER® editorial staff based on an online activity developed with these faculty.
              Release Date

              June 23, 2025

              Expiration Date

              June 23, 2026

              Off-Label Disclosure and Disclaimer

              This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

              25 min
            6. S2 Ep32: Breaking Barriers in HER2-Mutant NSCLC: Exploring the Promise of Next-Generation TKIs
              Episode Description
              In this episode of the PER® podcast, we explore the evolving landscape of HER2-mutant non–small cell lung cancer (NSCLC)—a rare and historically difficult-to-treat subset of lung cancer. Join Millie Das, MD, from Stanford/VA Palo Alto; and Eric Kumar Singhi, MD, from The University of Texas MD Anderson Cancer Center; as they delve into emerging clinical data on next-generation, HER2-selective tyrosine kinase inhibitors. Through expert insights and discussion of recent trial findings, this conversation highlights how novel targeted therapies are reshaping treatment strategies and providing new hope for patients with HER2-mutant NSCLC.

              Acknowledgment of Educational Grant Support
              This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Catalyst Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Exact Sciences Corporation; Janssen Biotech, Inc; and Partner Therapeutics, Inc.

              Accreditation/Credit Designation

              Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

              Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

              Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

              Instructions on How to Receive Credit
              1.       Listen to this podcast in its entirety. 
              2.       Go to gotoper.com/credit and enter code: 3462
              3.       Answer the evaluation questions.
              4.       Request credit using the drop-down menu.

              You may immediately download your certificate.

              Today’s faculty are:

              Millie Das, MD
              Chief, Oncology, VA Palo Alto Health Care System
              Clinical Professor, Stanford University
              Palo Alto, CA

              Disclosures: Grant/Research Support: CellSight, Genentech, Merck, Novartis, Varian; Consultant: AbbVie, Amgen (uncompensated), Bristol Myers Squibb, Catalyst, Daiichi Sankyo, EMD Serono, Genentech (uncompensated), Gilead, Guardant, Janssen, Merus, Natera, Novocure, Regeneron, Sanofi/Genzyme.

              Eric K. Singhi, MD 
              Assistant Professor 
              Department of General Oncology and Thoracic/Head and Neck Medical Oncology
              The University of Texas MD Anderson Cancer Center
              Houston, TX

              Disclosures: Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Caris Life Sciences, Janssen, Lilly, Novocure, Regeneron.

              The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

              PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

              Off-Label Disclosure and Disclaimer
              This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

              Release Date
              June 20, 2025

              Expiration Date
              June 20, 2026

              27 min
            7. S2 Ep31: Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
              Episode Description
              In this podcast, experts Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO, and Fred Hirsch, MD, PhD, review the evolving treatment landscape for limited-stage small-cell lung cancer (LS-SCLC) and extensive-stage (ES) SCLC, including a discussion of the latest strategies for managing common and severe treatment-related adverse events.

              Acknowledgment of Educational Grant Support
              This activity is supported by an educational grant from AstraZeneca.

              Accreditation/Credit Designation
              Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

              Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

              Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

              Instructions on How to Receive Credit
              1. Listen to this podcast in its entirety.
              2. Go to gotoper.com/credit and enter code: 3451
              3. Answer the evaluation questions.
              4. Request credit using the drop-down menu.
              5. You may immediately download your certificate.

                Today's faculty are:

                Fred Hirsch, MD, PhD, FASCO
                Professor of Medicine and Pathology
                Ning Zhao Chair Professor in Lung Cancer
                Executive Director, Center for Thoracic Oncology
                Associate Director of Biomarker Discovery, Tisch Cancer Institute
                Icahn School of Medicine at Mount Sinai
                New York, NY

                Disclosures: Advisory Board: AstraZeneca/Daiichi Sankyo, Agilent Technologies/Dako, Bristol Myers Squibb, Henlius/Fosun, Natera, Novartis Pharmaceuticals, Novocure, OncoHost

                Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO
                Director of Precision Oncology
                Cincinnati Cancer Advisors
                Cincinnati, OH

                Disclosures: Consultant: Amgen, AstraZeneca, Pfizer; Speakers’ Bureau: Amgen, Astellas Pharma, AstraZeneca, GSK, Pfizer

                The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

                PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

                Off-Label Disclosure and Disclaimer
                This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

                Release Date: June 18, 2025

                Expiration Date: June 18, 2026


                1 hr 5 min

              About PER Podcast Sessions

              From the publisher's feed

              Physicians' Education Resource® (PER®) is committed to advancing patient care through professional education. This podcast is a natural extension of PER®'s efforts to provide medical education for…